Triple therapy halves exacerbations in moderate-to-severe COPD (w/ Podcast)

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to researchers in Germany.

Read the whole article on Physorg

More from Physorg